Ceram signs agreement with AstraZeneca

Published: 18-Jan-2013
Research & Development

Will develop controlled release technology for delivery of selected AZ compounds


Anglo-Swedish pharmaceutical manufacturer AstraZeneca has signed an agreement with Ceram Research in which Ceram will develop its inorganic-based controlled release technology in a feasibility study for the delivery of selected AstraZeneca compounds.

‘This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds,’ said Tony Kinsella, CEO of Ceram, a materials development company headquartered in Stoke-on-Trent, Staffordshire, UK.

Controlled release technology is just one of the development projects that Ceram’s team of materials experts is currently working on; others include multi-element substituted hydroxyapatite for orthopaedic device coating applications.

  • Companies:
  • AstraZeneca
  • Lucideon
See more

You may also like

Research & Development

Fasenra for EGPA: addressing unmet needs

Read more
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  3. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  4. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Research & Development

Fasenra could initiate remission in patients with EGPA, study finds

MANDARA Phase III data highlights remission as an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with monthly subcutaneous injections of Fasenra
Manufacturing

Sodexo and AstraZeneca extend global partnership

Sodexo reinforces its contract of food and facilities management services with AstraZeneca in the UK, and Scandinavia for a further five years
Research & Development

Third cancer drug success for Astex drug discovery collaboration

AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN)
Research & Development

AstraZeneca meets primary endpoint in MANDARA Phase III trial

The pharma giant has revealed the results of the first head-to-head trial of biologics in EGPA, comparing a single monthly injection of the Fasenra drug to three injections per month of mepolizumab
Research & Development

AstraZeneca and Daiichi Sankyo reveal phase 3 lung cancer study

Results for the TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy
Subscribe now